<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052191</url>
  </required_header>
  <id_info>
    <org_study_id>KCG17121910001</org_study_id>
    <nct_id>NCT04052191</nct_id>
  </id_info>
  <brief_title>MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease</brief_title>
  <acronym>MCRcI®</acronym>
  <official_title>Intra-Coronary Administration of MCRcI® (Myo-Cardial Regenerative Cellular Injection) Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Honya Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Honya Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with
      Diffuse Coronary Artery Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant blind with dose.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricle stroke volume</measure>
    <time_frame>12 months</time_frame>
    <description>Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End diastolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
    <description>Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of angina symptom using Canadian Cardiovascular Society grading.</measure>
    <time_frame>12 months</time_frame>
    <description>Canadian Cardiovascular Society grading of angina pectoris is a classification system used to grade the severity of exertional angina. Scale ranges 0 ~ IV (most sever), with 0 Asymptomatic Angina, I Angina only with strenuous exertion, II Angina with moderate exertion, III Angina with mild exertion and IV Angina at rest.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose of MCRcI® stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate Dose of MCRcI® stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose of MCRcI® stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCRcI® stem cells</intervention_name>
    <description>Intra-Coronary Administration of MCRcI® stem cells</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Intermediate Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <other_name>stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Diffuse Coronary Artery Disease

          -  Age 20~80

          -  Participants have received proper medication

          -  Canadian Cardiovascular Society class II- IV Angina.

        Exclusion Criteria:

          -  Age &lt;20 or &gt;80

          -  Pregnant or breast feeding

          -  Positive adventitious infection (such as HIV, hepatitis )

          -  History of Myocardial Infarction within past 3 months

          -  Severe aortic or mitral valve narrowing

          -  Short of breath unable to receive PCI examination or treatment

          -  Malignant tumor

          -  Hematopoietic dysplasia

          -  Severe organ disease with less than 1 year of life expectancy

          -  Chronic kidney disease with CCr&lt;20ml/min

          -  Kiney disease on renal dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang Y Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jackson TK Liu, MD</last_name>
    <phone>+886921167980</phone>
    <email>honyamedical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HONYA Medical Inc</name>
      <address>
        <city>Tainan</city>
        <zip>74147</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackson TK Liu, MD</last_name>
      <phone>+88665055006</phone>
      <email>info@honyamedical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

